Back to Search
Start Over
Targeted therapy in gastric cancer
- Source :
- APMIS. 123:365-372
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Gastric cancer is often diagnosed at an advanced stage. Although chemotherapy prolongs survival and improves quality of life, the survival of gastric cancer patients with advanced disease is short. Thanks to recent insights into the molecular pathways involved in gastric carcinogenesis, new targeted treatment options have become available for gastric cancer patients. Trastuzumab, an antibody targeted to HER-2, was shown to improve survival of advanced gastric cancer patients harboring HER-2 overexpression due to gene amplification in their tumor cells, and is currently also explored in adjuvant and neoadjuvant settings. Another agent with promising results in clinical trials is ramucirumab, an antibody targeting VEGFR-2. No clear survival benefit, however, were experienced with agents targeting EGFR (cetuximab, panitumumab), VEGF-A (bevacizumab), or mTOR (everolimus). Drugs targeting c-MET/HGF are currently under investigation in biomarker-selected cohorts, with promising results in early clinical trials. This review will summarize the current status of targeted treatment options in gastric cancer.
- Subjects :
- Microbiology (medical)
Oncology
medicine.medical_specialty
Bevacizumab
Receptor, ErbB-2
medicine.medical_treatment
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Pathology and Forensic Medicine
Targeted therapy
Ramucirumab
Stomach Neoplasms
Trastuzumab
Internal medicine
medicine
Humans
Immunology and Allergy
Panitumumab
Molecular Targeted Therapy
Clinical Trials as Topic
Everolimus
Cetuximab
Hepatocyte Growth Factor
business.industry
TOR Serine-Threonine Kinases
Antibodies, Monoclonal
Cancer
General Medicine
Proto-Oncogene Proteins c-met
medicine.disease
Vascular Endothelial Growth Factor Receptor-2
3. Good health
ErbB Receptors
business
medicine.drug
Subjects
Details
- ISSN :
- 09034641
- Volume :
- 123
- Database :
- OpenAIRE
- Journal :
- APMIS
- Accession number :
- edsair.doi.dedup.....9c2e2ca43f1334c6f3c2183ab35b786c